Future Perspectives in Pharmacovigilance

ID# 12650 March 3-4, 2012 The Park, Bangalore, India



PROGRAM CO-CHAIRS

Moin Don

Executive Director PVCON, Pharmacovigilance Consulting Services

Dr Vivek Ahuja

Director, Pharmacovigilance Asia Pacific Baxter Healthcare

PROGRAM COMMITTEE

Dr B R Jagashetty

Drug Controller Karnataka State FDA

Dr Y K Gupta

Department Head, Clinical Pharmacology All India Institute of Medical Sciences

Prof. Parthasarthi Gurumurthy

Professor and Head, Department of Clinical Pharmacy JSS College of Pharmacy Medical College Hospital, Mysore

R K Giridhar

Vice President, BPO Pharma Services Accenture

Dr Chitra Lele

Chief Scientific Officer Sciformix Corp

INTERNATIONAL SPEAKERS

Stewart Geary

Vice President and Deputy Director of Corporate Regulatory Compliance, Safety and QA Eisai Co. Ltd. Japan

Dr Sidney Kahn

Principal Scientist Sciformix Pharmacovigilance Services

Dr Sumit Munjal

Consultant Physician (Oncology) Global Medical Safety Johnson & Johnson A divison of Janssen-Cilag Ltd, J & J, UK

Angela Pitwood

V.P. Pharmacovigilance Indipharm Inc. US

India Office

Drug Information Association 303, Wellington Business Park 1 Andheri-Kurla Road, Marol Andheri East, Mumbai 400059

Worldwide Headquarters

Drug Information Association, Inc. 800 Enterprise Road, Suite 200 Horsham, PA 19044, USA

Regional Offices

Basel, Switzerland Tokyo, Japan Mumbai, India Beijing, China

KEYNOTE SPEAKERS



Dr Y K Gupta
Department Head,
Clinical
Pharmacology
All India Institute of
Medical Sciences



Stewart Geary
Vice President and
Deputy Director of
Corporate Regulatory Compliance,
Safety & QA
Eisai Co. Ltd. Japan

PROGRAM CO-CHAIRS



Moin Don Executive Director PVCON Pharmacovigilance Consulting Services



Vivek AhujaDirector
Pharmacovigilance
Asia Pacific
Baxter Healthcare

HIGHLIGHTS

Ask the Experts

Join international pharmacovigilance experts for an open Q&A session to discuss your most difficult pharmacovigilance challenges.

DIA Special Interest Area Communities (SIACs)

FEATURED TOPICS

- Safety Management during Early Drug Development program
- US and EU Safety Regulation Updates - New FDA Rule / DSURs
- Safety and Regulatory Writing
- Medical Devices Vigilance
- Panel Discussion on Schedule Y and Empowerment to ECs/IRBs
- India as Pharmacovigilance Outsourcing Destination
- Safety during Clinical Trials through Medical Monitoring
- Integrating Pharmacovigilance in Medical and Para Medical Curriculum
- Utility of Cloud computing in Pharmacovigilance Database Domain

WHO SHOULD ATTEND

Professionals with experience in clinical safety and who are involved in:

- Pharmacovigilance
- Clinical research
- Risk management
- Compliance

- Medical information
- Regulatory affairs
- Academia
- Pharmacology

LEARNING OBJECTIVES

At the conclusion of this conference, participants will be able to:

- Explain key aspects of current global safety reporting requirements for prescription and over-the-counter drugs
- Discuss new pragmatic approaches to pharmacovigilance as proposed by the CIOMS working group
- Describe the regulatory agency clinical safety and pharmacovigilance inspection program in the US, Europe, and Japan
- Identify best practices for quality assurance in post marketing pharmacovigilance and clinical safety

All attendees will receive a DIA Certificate of Attendance at the conclusion of the event.



DAY 1 | SATURDAY, MARCH 3, 2012

8:00-9:00 AM **REGISTRATION**

9:00-9:15 AM **OPENING REMARKS**

Opening Remarks

Moin Don Dr Vivek Ahuia

Executive Director Director

Pharmacovigilance Asia Pacific **PVCON**

Baxter Healthcare

KEYNOTE ADDRESS 1 9:15-9:35 AM

The Lives and Times of Pharmaceutical Companies in Managing Ever Increasing Safety Regulations

Stewart Geary

Vice President and Deputy Director Corporate Regulatory Compliance, Safety and QA Eisai Co. Ltd. Japan

9:35-10:00 AM KEYNOTE ADDRESS 2

The Indian Pharmacovigilance Scenario An Introspection

Dr Y K Gupta

Department Head, Clinical Pharmacology All India Institute of Medical Sciences

10:00-10:15 AM **BREAKFAST**

10:15 AM-12:30 PM SESSION 1

The Vision For Pharmacovigilance

Ensuring High Returns Through Investments in the Future of Pharmacovigilance

Dr Vivek Ahuia

Director, Pharmacovigilance Asia Pacific Baxter Healthcare

11:00-11:45 AM

PV Systems in China and Japan

Stewart Geary

Vice President and Deputy Director of Corporate regulatory Compliance, Safety and QA Eisai Co. Ltd. Japan

Integrating Drug Safety Knowledge into the DNA of the Medical Educational System

Dr Urmila Thatte

Head of Department, Clinical Pharmacology Seth G.S. Medical College, Mumbai

Dr Y K Gupta

Department Head, Clinical Pharmacology All India Institute of Medical Sciences

12:30-1:30 рм LUNCH 1:30-4:45 PM SESSION 2

Regulatory Updates

1:30-2:30 PM

Panel Discussion: Indian Regulation/Schedule Y

Moin Don

Executive Director

PVCON

2:30-3:15 рм

An Overview of the New EU PV Regulation:

impact on PV Processes

Sumit Verma

Head of PV, EU Operations

APCER

3:15-3:30 рм **TEA**

3:30-4:15 рм

The Practical implications of New FDA Rule and DSURs

Dr Sidney Kahn

Principal Scientist

Sciformix Pharmacovigilance Services

European Pharmacovigilance Regulatory Perspective and Latest Developments

Dr Sumit Munial

Consultant Physician (Oncology)

Global Medical Safety

Johnson & Johnson

A divison of Janssen-Cilag Ltd , J & J, UK

4:45-5:45 рм **SESSION 3**

Technology Updates

4:45-5:15 PM

Online Signal Management - A System Based Approach

Ravinder Singh

APAC Director - HSGBU, Sales Consulting

Oracle Health Sciences

Application of Cloud Computing to Fortify the Science

of Pharmacovigilance

Vikram Anand

Head agOnDemand

ArisGlobal

DAY 2 | **SUNDAY, MARCH 4, 2012**

9:00-10:30 AM **SESSION 4**

Industry Perspective - Outsourcing

9:00-9:30 AM

Global PV Outsourcing - Trends and Challenges

Madhur Rathaur

Director

PWC's PRTM Management Consulting

9:30-10:00 AM

Setting Up Case Processing Unit

Dinesh Kasthuril

Director - Pharmacovigilance Services

Sciformix Technologies

Ensuring Quality Through Metrics and SLA Challenges

in a Case Processing Environment

Shrish Sherlekar

Group Head, Life Sciences Practice

TCS

10:30-10:45 AM BREAKFAST

10:45 AM-1:00 PM SESSION 5

Industry Perspective - Best Practices

10:45-11:15 AM

People Management Strategies

R K Giridhar

Vice President, BPO Pharma Services

Accenture

11:15-12:00 PM

Elements For Successful Pharmacovigilance Agreements

Angela Pitwood

Vice President Pharmacovigilance Indipharm Inc., US

12:00-12:30 PM

Safety and Regulatory Writing

Gunjan Shah

Project Manager, Medical Writing Sciformix Technologies Ltd.

12:30-1:00 PM

Signal Detection Through Conventional Methods and Data Minning

Ajoy Roy

Senior Medical Director PAREXEL India

1:00-1:45 рм

LUNCH

1:45-3:45 PM SESSION 6

PV Through Drug Development Phase

1:45-2:45 PM

Panel Discussion: Empowering ECs/IRB

for Safety Assessment

Dr Chitra Lele

Chief Scientific Officer Sciformix Corp 2:45-3:15 PM

Safety Consideration During Early Phase Drug Development

Nipom Deka

Global Pharmacovigilance Regional Head - Asia Pacific Glenmark

3:15-3:45 рм

Challenges in Ensuring Protocol Compliance and Patient Safety

Aparna Kalsekar

Head - Medical Services SIRO Clinpharm Pvt. Ltd.

3:45-4:00 PM TEA

4:00-5:00 PM SESSION 7

PV Stake-Holders Perspective

4:00-4:30 PM

Spontaneous Reporting in Hospital Set Up

Prof Parthasarthi Gurumurthy

Professor and Head, Department of Clinical Pharmacy JSS College of Pharmacy Medical College Hospital, Mysore

4:30-5:00 PM

Practicing PV during General Practice

Dr Sandeep Bavdekar

Professor and Head, Department of Pediatrics TN Medical College & BYL Nair Hospital

5:00 PM CONFERENCE ADJOURNED

Unless otherwise disclosed, DIA acknowledges that the statements made by speakers are their own opinion and not necessarily that of the organization they represent, or that of the Drug Information Association.

Speakers and agenda are subject to change without notice.

Recording of any DIA tutorial/workshop information in any type of media, is prohibited without prior written consent from DIA.





DIA India Membership

DIA is the premier professional member association in the world addressing solutions to issues and challenges across the entire drug development industry. DIA's professional development opportunities, timely information resources and global network of thought leaders allow you to take control of your career.

- Participate in our neutral, global forum, completely independent from the influence of any one organization or authority
- Learn about regulations, best practices and trends from industry thought leaders
- Connect with and learn from regulatory, industry, and academic professionals while advancing your career through conferences, networking opportunities and DIA's knowledge resources
- Take advantage of all these member benefits join DIA today!

Standard Membership

Student Membership

Annual Fee: Rs. 1950 (inclusive of taxes)

Annual Fee: Rs. 800 (inclusive of taxes)

To know more contact:

Rhean D'Souza | Tel: +91.22.2859.4762 | Cell: +91.98.2058.7798 Email: Rhean.Dsouza@diaindia.org

TRAVEL AND HOTEL

Attendees should make airline reservations as early as possible to ensure availability. The Park Bangalore is holding a block of rooms at the reduced rate below until February 10, 2012, for the DIA event attendees. Room availability at this rate is guaranteed only until this date or until the block is filled.

Single/Double INR 6000 + Taxes

is located at 14/7 Mahatma Gandhi Road, Bangalore 560042, India

Contact Person: Sudhanshu Singh, Phone: +91.80.2559.4666 Fax: +91.80.2559.4667 Email: ssingh@theparkhotels.com

MEETING CONTACTS

MEETING MANAGER: Manoj Trivedi, Senior Manager

Marketing and Program Development, DIA (India) Private Limited

Cell: +91.98.1977.7493

email: Manoi.Trivedi@diaindia.org

DELEGATE AND TABLETOP REGISTRATION: Rhean D'Souza, Assistant Manager

Marketing and Program Development, DIA (India) Private Limited

Tel: +91.22.2859.4762, Cell: +91.98.2058.7798 email: Rhean.Dsouza@diaindia.org

CANCELLATION POLICY: On or before JANUARY 15, 2012

Cancellations must be in writing and received by January 15, 2012. Registrants who do not cancel in writing by that date and do not attend the event will be responsible for the full registration fee paid. Registrants are responsible for cancelling their own hotel and airline reservations. If the event is cancelled, DIA is not responsible for any airfare, hotel or other costs incurred by registrants.

DIA reserves the right to alter the venue, if necessary. If an event is cancelled, DIA is not responsible for any airfare, hotel or other costs incurred by registrants.

will be withheld from refund amount is:

Upon cancellation, the administrative fee that | FULL MEETING CANCELLATION (All refunds will be issued in the currency of original payment): Member/Nonmember Registration = INR 3,000 • Student Registration = INR 500

PLEASE CONSIDER THIS FORM AS AN INVOICE

FUTURE PERSPECTIVES IN PHARMACOVIGILANCE

Meeting I.D. # 12650 - March 3-4, 2012 - The Park Bangalore, Bangalore, INDIA

REGISTRATION FEES Registration fee includes refreshment breaks, luncheons, and will be accepted by mail or fax.

Join DIA now to qualify to save on future events and to receive all the benefits of membership. To see all the benefits of DIA membership, visit www.diahome.org and click on Membership.

| MEMBER | | | | | | |
|----------|------------|-------|------------|--|--|--|
| | BASIC RATE | TAXES | TOTAL | | | |
| Industry | 5698 | 352 | □ INR 6050 | | | |
| Academia | 3767 | 233 | □ INR 4000 | | | |
| Student* | 2825 | 175 | □ INR 3000 | | | |

| NONMEMBER (Inclusive of Membership) | | | | | |
|-------------------------------------|------------|-------|------------|--|--|
| | BASIC RATE | TAXES | TOTAL | | |
| Industry | 7466 | 534 | □ INR 8000 | | |
| Academia | 5582 | 418 | □ INR 6000 | | |
| Student* | 2825 | 175 | □ INR 3000 | | |

*A limited number of student registrations are available.

Total Amount Due

A student is an undergraduate/graduate who can document enrollment in a Signature accredited, degree granting, academic program. Please send completed registration form, copy of student identification, and payment.

REGISTRATION TERMS AND CONDITIONS: Registration form should be duly filled, signed by the authorized person. You are requested to email the duly filled and signed Registration Form first and then courier/mail it along with registration fees on or before 5 working days

| Please check the applicable category: Academia Government Industry CRO Non-Member Member: Customer ID No.: | | PAYMENT INFORMATION Completed form, along with draft/cheque made payable to DIA (India) Private Limited should be sent to: Rhean D'Souza DIA (India) Private Limited, A-303, Wellington Business Park | | |
|--|-----------------------------------|---|---|--|
| Degrees: | □ Dr. □ Mr. □ Ms. | Andheri-Ku | urla Road, Marol, Andheri (East), Mumbai 400 059 .22.6765.3226 | |
| Last Name (Family Name) | | _ | | |
| First Name | M.I. | | | |
| Job Title | | | | |
| Affiliation (Company) | | | | |
| Address (Please write your address in the format required | ☐ Business Address ☐ Home Address | | | |
| Postal Code City | | State | Country | |
| Telephone Number | Fax Number | | Mobile Number | |
| email (Required for confirmation) | | | Signatory | |
| Payment contact person's Full Name | Telephone Number | | Email | |

Organisation PAN no